Rigel Pharmaceuticals (RIGL) Operating Income Growth (3y) (2013 - 2026)
Rigel Pharmaceuticals (RIGL) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 55.96% |
| 10 | Rigel Pharmaceuticals | 702.97 Mn | 556.29 Mn | 54.21 Mn | 43.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.16% |
| Dec 31, 2025 | 123.37% |
| Sep 30, 2025 | 52.47% |
| Jun 30, 2025 | 88.64% |
| Mar 31, 2025 | 35.47% |
| Dec 31, 2024 | 40.57% |
| Sep 30, 2024 | 39.43% |
| Jun 30, 2024 | 26.71% |
| Mar 31, 2024 | -29.40% |
| Dec 31, 2023 | 28.15% |
| Sep 30, 2023 | 31.32% |
| Jun 30, 2023 | 32.85% |
| Mar 31, 2023 | -37.60% |
| Dec 31, 2022 | 28.46% |
| Sep 30, 2022 | -15.20% |
| Jun 30, 2022 | 15.30% |
| Mar 31, 2022 | -12.63% |
| Dec 31, 2021 | -118.69% |
| Sep 30, 2021 | 6.71% |
| Jun 30, 2021 | 20.65% |